| Spironolactone therapy is associated with reduced ventricular tachycardia rate in patients with cardiomyopathy. | |
| | |
MedLine Citation:
|
PMID: 20946289 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
INTRODUCTION: Multiple pharmacological therapies currently in prevalent clinical use for cardiac diseases have antifibrotic properties. Spironolactone, a potent antifibrotic agent, is currently used for advanced heart failure. Therapies such as HMG-CoA reductase inhibitors (statins) and angiotensin-converting enzyme inhibitors (ACEi) also have antifibrotic properties. However, the effect of these medications on the ventricular arrhythmia phenotype is currently unknown. Therefore, we set out to define the ventricular arrhythmia rates in patients actively treated with such therapies. METHODS AND RESULTS: We retrospectively evaluated the ventricular tachycardia (VT) rates in patients with structural heart disease actively treated with therapies with antifibrotic properties. VT rates were significantly diminished in patients treated with spironolactone (158 ± 26 beats per minute [bpm], n = 21) compared to patients on no medications (205 ± 22 bpm, n = 13) or those who were on similar heart-failure therapies but not on spironolactone (186 ± 32 bpm, n = 82). In addition, we observed that VT rates showed a significant trend toward lower rates in patients receiving either statins or ACEi, compared to patients on no medical therapy. In multivariate analysis, spironolactone therapy was identified as the single most significant variable for reduced VT rate. CONCLUSION: Use of spironolactone in patients with heart failure is associated with reduced VT rate. Similar but less-significant reductions in VT rates were observed with use of other pharmacological agents with antifibrotic properties, such as statins and ACEi. Our findings, at least in part, could account for reduction in sudden cardiac death rates documented with use of these therapies. |
| | |
Authors:
|
Vassilis Dimas; Colby Ayers; James Daniels; Jose A Joglar; Joseph A Hill; R Haris Naseem |
Related Documents
:
|
11502049 - Left ventricular epicardial outflow tract tachycardia: a new distinct subgroup of outfl... 19187909 - Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoido... 20546149 - Anterior mitral valve length is associated with ventricular tachycardia in patients wit... 1516189 - Combined use of time and frequency domain variables in signal-averaged ecg as a predict... 19302479 - Catheter ablation of idiopathic ventricular tachycardia arising from the aortic root. 17627109 - Stable and unstable ventricular tachycardias in patients with previous myocardial infar... 22265909 - Coronary vasospasm induced in transgenic mouse with the increased phospholipase c-δ1 a... 23555019 - Cyp2c19 phenotype, stent thrombosis, myocardial infarction, and mortality in patients w... 7627659 - A comparison of clinical index and ejection fractions in predicting cardiac complicatio... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2010-10-14 |
Journal Detail:
|
Title: Pacing and clinical electrophysiology : PACE Volume: 34 ISSN: 1540-8159 ISO Abbreviation: Pacing Clin Electrophysiol Publication Date: 2011 Mar |
Date Detail:
|
Created Date: 2011-03-08 Completed Date: 2011-08-09 Revised Date: 2013-04-08 |
Medline Journal Info:
|
Nlm Unique ID: 7803944 Medline TA: Pacing Clin Electrophysiol Country: United States |
Other Details:
|
Languages: eng Pagination: 309-14 Citation Subset: IM |
Copyright Information:
|
©2010, The Authors. Journal compilation ©2010 Wiley Periodicals, Inc. |
Affiliation:
|
Department of Internal Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, Texas 75390-8573, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Aged Cardiomyopathies / drug therapy*, epidemiology* Comorbidity Diuretics / therapeutic use Female Heart Rate / drug effects Humans Male Middle Aged Prevalence Risk Assessment Risk Factors Spironolactone / therapeutic use* Tachycardia, Ventricular / drug therapy*, epidemiology* Texas / epidemiology Treatment Outcome |
| Grant Support | |
ID/Acronym/Agency:
|
HL-075173/HL/NHLBI NIH HHS; HL-080144/HL/NHLBI NIH HHS; HL-090842/HL/NHLBI NIH HHS; P30 HL101254/HL/NHLBI NIH HHS; R01 HL075173/HL/NHLBI NIH HHS; R01 HL080144/HL/NHLBI NIH HHS; R01 HL090842/HL/NHLBI NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Diuretics; 52-01-7/Spironolactone |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Transplantation of liver organoids in the omentum and kidney.
Next Document: Trends of temporary pacemaker implant and underlying disease substrate.